JAM-A, His, Human
JAM-A, His, Human

JAM-A, His, Human, His Tag at 1 μg/ml (100 μl/Well) on the plate. Dose response curve for Anti-JAM-A Antibody, hFc Tag with the EC50 of 2.4 ng/ml determined by ELISA.

JAM-A, His, Human

JAM-A, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

JAM-A, His, Human

junctional adhesion molecule A (JAM-A), a cell adhesion molecule, is highly elevated in human GBM cancer stem cells and predicts poor patient prognosis. While JAM-A is also highly expressed in other cells in the tumor microenvironment, specifically microglia and macrophages,JAM-A functions to suppress pathogenic microglial activation in the female tumor microenvironment, highlighting an emerging role for sex differences in the GBM microenvironment and suggesting that sex differences extend beyond previously reported tumor cell-intrinsic differences.
Z05540
¥69,021.00

Ask us a question
Product Introduction
Species Human
Protein Construction
JAM-A (Ser28-Val238)_x000D_
Accession # Q9Y624-1		 His
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 24 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 28-35 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • JAM-A, His, Human
    • JAM-A, His, Human

    JAM-A, His, Human, His Tag at 1 μg/ml (100 μl/Well) on the plate. Dose response curve for Anti-JAM-A Antibody, hFc Tag with the EC50 of 2.4 ng/ml determined by ELISA.

  • JAM-A, His, Human
    • JAM-A, His, Human

    JAM-A, His, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background junctional adhesion molecule A (JAM-A), a cell adhesion molecule, is highly elevated in human GBM cancer stem cells and predicts poor patient prognosis. While JAM-A is also highly expressed in other cells in the tumor microenvironment, specifically microglia and macrophages,JAM-A functions to suppress pathogenic microglial activation in the female tumor microenvironment, highlighting an emerging role for sex differences in the GBM microenvironment and suggesting that sex differences extend beyond previously reported tumor cell-intrinsic differences.
Synonyms JAM-A; JAM-1; CD321; JAM; JCAM; JCAM1; KAT; PAM-1; F11 receptor; F11R; PAM-1KAT

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.